FIELD: biotechnology; endocrinology; obstetrics.
SUBSTANCE: invention relates to biotechnology, namely to endocrinology and obstetrics, it can be used to select patients for a molecular genetic study (MGS) to confirm a mutation in the GCK/MODY2 gene.
EFFECT: invention is aimed at simplifying and reducing the cost of diagnostics of MODY2 diabetes mellitus by reducing the number of pregnant women sent for MGS.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING GLYCEMIC VARIABILITY TO DETERMINE EFFECTIVENESS OF ANTIHYPERGLYCEMIC THERAPY IN PATIENTS WITH MODY2 DIABETES | 2020 |
|
RU2746830C1 |
| METHOD FOR PREDICTION OF RISK OF GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN | 2019 |
|
RU2716268C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING GESTATIONAL DIABETES | 2015 |
|
RU2589663C1 |
| METHOD FOR PREDICTION OF GESTATIONAL DIABETES MELLITUS IN WOMEN PLANNING PREGNANCY | 2023 |
|
RU2816803C1 |
| METHOD OF DIAGNOSING GESTATIONAL DIABETES MELLITUS | 2013 |
|
RU2557978C2 |
| METHOD OF PREVENTING GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN DEPENDING ON GENDER OF FETUS | 2022 |
|
RU2810451C1 |
| METHOD FOR PREDICTING FETOPATHY IN PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS IN THE MIDDLE OF PREGNANCY | 2017 |
|
RU2667129C1 |
| METHOD FOR INDIVIDUAL PREVENTION OF OESTROGEN-DEPENDENT DISEASES AND REPRODUCTIVE DISORDERS IN FEMALES AT AGE OF 18-35 YEARS OLD SUFFERING METABOLIC DISORDERS | 2013 |
|
RU2527358C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING FETAL MACROSOMIA IN PATIENTS WITH GESTATIONAL DIABETES MELLITUS AFTER USING ASSISTED REPRODUCTIVE TECHNOLOGIES | 2023 |
|
RU2819022C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF THERAPY USING ORAL HYPOGLYCEMIC AGENT METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | 2015 |
|
RU2602663C1 |
